| Project/Area Number |
17K11496
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Ophthalmology
|
|---|
| Research Institution | Osaka Medical College |
|---|
Principal Investigator |
Kojima Shota 大阪医科大学, 医学部, 准教授 (10388259)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
杉山 哲也 大阪医科大学, 医学部, 非常勤講師 (20298764)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2017: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | 緑内障 / 濾過手術 / 眼圧 / 瘢痕 / レゴラフェニブ / マルチキナーゼ阻害薬 / 濾過胞 / 線維化 |
|---|
| Outline of Final Research Achievements |
This study aimed to investigate the effects of regorafenib on intraocular pressure (IOP), bleb formation, and conjunctival changes in experimental glaucoma filtration surgery models. Glaucoma filtration surgery models were created in 24 eyes of 24 beagles. In experiment 1 (Ex 1), regorafenib eye drops or vehicle were instilled twice daily for 4 weeks postoperatively. In experiment 2 (Ex 2), regorafenib eye drops were instilled as in Ex 1 for 12 weeks while conventional intraoperative mitomycin-C (MMC) was utilized , In Ex 1, only the regorafenib group showed significant IOP reduction with a significantly higher bleb score. In Ex 2, no significant difference was found in IOP reduction and bleb formation between the regorafenib and MMC groups; bleb walls were significantly thicker and collagen density and vessels were higher in the regorafenib group. . Thus, regorafenib might be a better alternative to MMC for creating thicker and less ischemic blebs in glaucoma filtration surgery.
|
| Academic Significance and Societal Importance of the Research Achievements |
緑内障の治療は眼圧下降が最も効果的であり、代表的な眼圧下降手術である線維柱帯切除術は眼圧下降維持のために結膜濾過胞を形成する必要があり、術後結膜瘢痕癒着抑制を目的として手術時にマイトマイシンC(MMC)などの線維芽細胞増殖抑制薬を用いている。しかし濾過胞感染など重篤な術後副作用が問題となっており、これに代わる薬剤が必要とされている。今回、イヌ緑内障手術モデル眼においてレゴラフェニブ点眼によってMMCと同等の眼圧下降・濾過胞維持効果が示され、より壁が厚く、血管やコラーゲンに富む濾過胞が形成される事が示された。すなわちMMC使用と同等の効果とより安全な結果が得られる可能性が示唆された。
|
